Assembly Biosciences
ASMB
54 hedge funds and large institutions have $36.1M invested in Assembly Biosciences in 2022 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 12 increasing their positions, 22 reducing their positions, and 6 closing their positions.
16,600% more call options, than puts
Call options by funds: $167K | Put options by funds: $1K
0% more funds holding
Funds holding: 54 → 54 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
4% less ownership
Funds ownership: 39.65% → 35.65% (-4%)
45% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 22
54% less capital inflows, than outflows
Capital inflows: $3.36M | Capital outflows: $7.36M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$1.23M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.2M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$281K |
| 4 |
Renaissance Technologies
New York
|
+$175K |
| 5 |
Two Sigma Investments
New York
|
+$120K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Armistice Capital
New York
|
-$4.12M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$705K |
| 3 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$610K |
| 4 |
Eversept Partners
New York
|
-$577K |
| 5 |
Ikarian Capital
Dallas,
Texas
|
-$468K |
ASMB Hedge Fund Activity: Q2 2022 in Review
54 of the 5,962 institutional investors tracked by Wall St. Rank reported a position in Assembly Biosciences (ASMB) for Q2 2022, worth a combined $36.1M — down 8.2% from $39.3M a quarter earlier.
Fund positioning in ASMB was balanced in Q2 2022: 6 funds opened new positions, 6 closed out, 12 added to existing stakes and 22 trimmed.
The largest buyer was Assenagon Asset Management, adding an estimated $1.23M. The largest seller was Armistice Capital, exiting entirely with an estimated $4.12M sold.
- 54 institutional investors held Assembly Biosciences (ASMB) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $36.1M of Assembly Biosciences stock for Q2 2022, down 8.2% quarter-over-quarter.
- 6 funds opened new Assembly Biosciences positions in Q2 2022 and 6 closed out, a net change of 0 holders.
- The largest Assembly Biosciences buyer in Q2 2022 was Assenagon Asset Management, an estimated $1.23M added.
- The largest Assembly Biosciences seller in Q2 2022 was Armistice Capital, an estimated $4.12M sold.
Based on aggregated 13F filings for Q2 2022.